BOSTON, SHANGHAI, and SUZHOU – September 24, 2025, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced today that it will be participating in two premier industry conferences in October:
1. RNA Leaders APAC 2025 | Marina Bay Sands, Singapore (October 15-16)
Presentation – October 15, 14:50pm (UTC+08:00)
Speaker: Dr. Weimin Wang, Founder and CEO
Link: https://informaconnect.com/rna-leaders-apac/
Dr. Weimin Wang, founder and CEO of SanegeneBio, will share an update on our obesity and cardiometabolic programs, powered by the LEAD™ RNAi technology platform. LEAD™ enables selective extrahepatic delivery to adipose and muscle tissue after infrequent subcutaneous administration.
2. 21st Annual Meeting of the Oligonucleotide Therapeutics Society (OTS 2025) | Budapest Congress Center, Hungary (October 19-22)
Presentation – October 20, 16:15pm (UTC+2)
Speaker: Dr. Marc Abrams, CTO and Head of U.S. R&D Operations
Link: https://www.2025oligomeeting.com/
Dr. Marc Abrams, our CTO and Head of US Operations, will share an update on SGB-9768 and SGB-3383, two clinical-stage experimental RNAi medicines targeting C3 and CFB, respectively, for complement-related diseases. Future innovations in RNAi delivery using SanegeneBio’s LEAD™ technology will also be highlighted.
We warmly invite investors, partners, and industry peers attending these conferences to connect with us.
About SanegeneBio
SanegeneBio is a global, venture-backed, fully-integrated biotechnology company focused on developing RNAi-based therapeutics. Founded in 2021, SanegeneBio is led by a team of RNAi pioneers with unrivaled experience in this Nobel Prize-winning technology. With R&D operations in Boston, Shanghai and Suzhou, our vision clear – RNAi technology will power blockbuster medicines in diverse therapeutic areas, improving the quality and longevity of life for countless patients in the coming years. Our fast-growing pipeline includes experimental medicines for autoimmune nephropathies, obesity, and cardiometabolic indications. SanegeneBio has initiated clinical trials for several experimental medicines, and is committed to developing potential best-in-class and first-in-class therapeutics which leverage our industry-leading and differentiated LEAD™ tissue-selective RNAi delivery technology. For more information, please visit: www.sanegenebio.com and engage with us on LinkedIn.